Dr. Adam S. Cheifetz, MD

Dr. Cheifetz practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Cheifetz's NPI, 1811934417, was assigned on June 1, 2006. Dr. Cheifetz graduated from JS Weill Medical College, Cornell University in 1997. Dr. Cheifetz holds Massachusetts license 220642.

Dr. Cheifetz's primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Cheifetz's primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Cheifetz is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Cheifetz to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cheifetz practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Cheifetz's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Cheifetz is licensed in Massachusetts.

CMS data shows 245 Medicare services from Dr. Cheifetz across 4 procedure codes in 2024, for 126 Medicare patients. Medicare paid $17,301 for them.

CMS counts 126 Medicare patients who saw Dr. Cheifetz in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 17% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cheifetz's median patient age at 60, with 45% women.

In 2024, Dr. Cheifetz wrote 368 Medicare Part D claims for 108 patients. 59% of them were for generic drugs. CMS names the drug for 251 of them, across 8 drugs with 11 or more claims each, at $1,762,745 in total drug cost. In 2023, CMS named 273 claims across 10 drugs.

Dr. Cheifetz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cheifetz as offering telehealth. CMS counts 58 procedures of colonoscopy by Dr. Cheifetz, more than 67% of the clinicians it reports for that procedure.

Dmand AI links 175 papers to Dr. Cheifetz, published from 2011 to 2025. 2016 was the busiest year, with 10. The most frequent topics are Inflammatory Bowel Diseases, Crohn Disease and Infliximab. Dr. Cheifetz has published most often in Inflamm Bowel Dis. Dr. Cheifetz's most frequent co-authors are Joseph D. Feuerstein, MD, Daniel Alexander Leffler, MD and Byron P. Vaughn, MD.

Dmand AI links Dr. Cheifetz to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Colitis, Ulcerative, Diabetes Mellitus, Type 2 and Colitis. Open Payments lists research payments to Dr. Cheifetz that name 1 trial.

CMS Open Payments shows 461 general payments to Dr. Cheifetz from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 47% of the total. Abbvie Inc. paid the most, $225,883. It also lists 11 research payments totaling $11,410 from 2016 to 2019, naming 1 clinical trial.

Dr. Cheifetz graduated from JS Weill Medical College, Cornell University in 1997.